Purity, aggregation state, and target binding are critical quality requirements that need to be monitored throughout the antibody development cycle as they impact product efficacy and safety. Yet, ...

In this free webinar, gain insight into how FACS-guided single B-cell sorting preserves native heavy/light chain pairing and enables high-throughput antigen-specific screening. Attendees will learn ...

Antibodies (immunoglobulins) are Y-shaped proteins that recognize and neutralize specific pathogens. Their ability to target specific molecules or cells has made them promising candidates for future ...

In this webinar, brought to you by The Antibody Society (MA, USA), in association with the journal mAbs, Drs. Crescioli and Reichert discuss the recent trends in antibody therapeutics development ...

Novel or next-generation biologics such as bispecific antibodies (bsAbs) and fusion proteins present unique development and manufacturing process challenges due to complex formats, suboptimal ...

Antibodies, as powerful therapeutic agents, have demonstrated immense potential in treating a range of diseases, from cancer to infectious diseases. Recent advances in artificial intelligence (AI) and ...

Antibodies hold promise as therapeutic agents. However, their tendency to aggregate poses significant challenges to drug development. In a groundbreaking study, researchers now provide novel insights ...

Antibodies (immunoglobulins) are Y-shaped proteins that recognize and neutralize specific pathogens. Their ability to target specific molecules or cells has made them promising candidates for future ...

Biotherapeutic pipelines don’t just juggle monoclonal antibodies anymore, they need to be ready for protein conjugates like ADCs and for teeny tiny peptides. Even beyond new modalities, automation is ...

Thank you to everyone who attended our webinar ‘Antibodies to watch in 2026‘ in association with the journal, mAbs. Below are responses from speakers Janice Reichert and Silvia Crescioli to the ...